Table 2.

Consistent CNAs observed in chemotherapy responsive vs. primary refractory HL, not observed in germinal center cells.

Band	Region	Event	Length (bp)	Freq. in Ref	Freq.in Sen.	Genes in Sen pts
16q13	chr16:55,456,619-56,127,978	Gain	671,359	25%	60%	ARL2BP, CCDC102A, CCL17, CCL22, CETP, CIAPIN1, COQ9, CPNE2, CX3CL1, DOK4, HERPUD1, NIP30, NLRC5, PLLP, POLR2C, RSPRY1, SLC12A3
16p11.2	chr16:32,592,341-33,172,220	Loss	579,879	17%	53%	LOC729355, TP53TG3
Band	Region	Event	Length (bp)	Freq. in Ref	Freq. in Sen.	Genes in Ref Pts
1q21.2	chr1:148,603,613-148,818,760	Loss	215,147	42%	7%	ADAMTSL4, ECM1, KIAA0460, MCL1, TARS2
2q37.2	chr2:236,067,474-236,698,859	Gain	631,385	50%	27%	CENTG2
4q27	chr4:120,634,997-123,761,662	Loss	3,126,665	50%	20%	ADAD1,ANXA5, BBS7, C4orf31,CCNA2, EXOSC9, GPR103, IL2,IL21,KIAA1109, MAD2L1, PDE5A, TMEM155, TNIP3, TRPC3
5p15.31	chr5:7,449,342-7,883,194	Loss	433,852	42%	0%	ADCY2
5p15.2	chr5:9,088,137-9,683,463	Loss	595,326	42%	7%	SEMA5A,TAS2R1
11p14.3	chr11:22,171,297-22,257,975	Loss	86,678	58%	7%	TMEM16E
13q31.2	chr13:87,122,870-87,129,871	Gain	7,001	58%	27%	SLITRK5
17p12	chr17:11,864,859-15,526,918	Loss	3,662,059	58%	13%	CDRT1, CDRT15, CDRT4, COX10, ELAC2, FAM18B2, FLJ45831,HS3ST3A1, HS3ST3B1, MAP2K4, MYOCD, PMP22, RICH2, TEKT3, TRIM16
19q13.31	chr19:49,894,197-49,955,141	Gain	60,944	50%	20%	BCL3,RELB, CEACAM19
22q13.33	chr22:49,092,963-49,100,010	Gain	7,047	50%	20%	FAM116B